Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma

Forner, 2018, Hepatocellular carcinoma, Lancet, 391, 1301, 10.1016/S0140-6736(18)30010-2 Covey, 2017, Liver-directed therapy for hepatocellular carcinoma: an overview of techniques, outcomes, and post-treatment imaging findings, AJR Am J Roentgenol, 209, 67, 10.2214/AJR.17.17799 Wu, 2018, CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study, World J Surg Oncol, 16, 69, 10.1186/s12957-018-1368-8 Huang, 2014, Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma, J Gastroenterol Hepatol, 29, 920, 10.1111/jgh.12439 Megías Vericat, 2015, Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: a study of effectiveness, safety and costs, Radiologia, 57, 496, 10.1016/j.rx.2015.01.008 Lu, 2017, Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial, Cancer Biol Ther, 18, 433, 10.1080/15384047.2017.1323589 Zhen, 2018, The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study, J Cancer, 9, 2773, 10.7150/jca.26376 Cosgrove DP, 2015, Open-label single-arm phase ii trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results, Radiology, 277, 594, 10.1148/radiol.2015142481 Yang, 2019, The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study, Cancer Biol Ther, 20, 321, 10.1080/15384047.2018.1529099 Pawlik, 2011, Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma, J Clin Oncol, 29, 3960, 10.1200/JCO.2011.37.1021 Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086 Seyal, 2015, Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma, Hepatology, 62, 1111, 10.1002/hep.27915 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Aliberti, 2017, Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience, Future Oncol, 13, 2243, 10.2217/fon-2017-0364 Facciorusso, 2016, Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis, Dig Liver Dis, 48, 571, 10.1016/j.dld.2016.02.005 Wang, 2019, Tumor hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and sorafenib for intermediate hepatocellular carcinoma, BMC Cancer, 19, 409, 10.1186/s12885-019-5570-z Qin, 2014, Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase II randomized, open-label trial, J Clin Oncol, 32, 4019, 10.1200/jco.2014.32.15_suppl.4019 Lee, 2017, Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study, Acta radiologica, 58, 131, 10.1177/0284185116648501 Xiao, 2019, Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience, Cancer Manage Res, 11, 1551, 10.2147/CMAR.S193948 Chen, 2018, Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma, BMC Cancer, 18, 1131, 10.1186/s12885-018-5081-3